Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NEEDLE-BEARING DEVICE PERFORMANCE STANDARD DEVELOPMENT BY FDA

This article was originally published in The Gray Sheet

Executive Summary

NEEDLE-BEARING DEVICE PERFORMANCE STANDARD DEVELOPMENT BY FDA would be mandated under legislation introduced March 10 by Rep. Pete Stark (D-Calif.). The bill (H.R. 1304) states that not later than one year after enactment, FDA "shall prescribe safety performance standards for syringes" and "such components of intravenous systems as" FDA "deems appropriate" for "purposes of preventing accidental needlestick injuries to health care providers." The agency also would be required to "consult with appropriate private sector experts" in developing or revising the standard, which would be reassessed annually by the agency. The bill, which is similar to legislation introduced by Stark in February 1992, lends support to one portion of a petition pending at FDA. The petition, submitted by the Service Employees International Union in April 1991, asks the agency to develop a performance standard for needle-bearing devices, reclassify the devices into Class III and deem all needlestick injuries reportable events under medical device reporting regulations ("The Gray Sheet" April 27, 1992, I&W-8). The Stark bill also would temporarily impose a 10 cents excise tax on the "taxable sale" of syringes and intravenous items that do not meet the performance standard. The tax would go into effect on Jan. 1, 1997 and would be terminated three years later. Stark is proposing the needle tax to "ensure a mass-market for safe needles and provide the necessary production economies of scale to ensure low prices," a press release on the bill notes. The tax would not be imposed until 1997 "to give manufacturers, marketers and health care facilities ample time to develop the most reliable, low-cost, mass-produced safe needles possible." The bill defines taxable sale as "any sale of a taxable medical item to a health care provider for use in the United States in providing health care services, but only if such sale is the first sale to such a provider for such use after manufacture, production, or importation."

You may also be interested in...



US FDA Still Seeking Sponsor Cooperation For Oncology Label Updates

Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.

Oncology Drug Safety Is Key Focus In US FDA’s Generic Label Updates

US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.

EU GMP Annex I Proposal Would Maintain PUPSIT, Relax WFI Restrictions

The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.

UsernamePublicRestriction

Register

MT000332

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel